3M Licenses Technology to STADA Arzneimittel for Fentanyl Transdermal Patch
3M Drug Delivery Systems is reporting that STADA Arzneimittel AG has licensed 3M’s patented technology directed to a matrix patch for the transdermal delivery of the opioid pain medication fentanyl.
According to 3M, its patent "enables a transdermal drug delivery device designed to deliver a therapeutically effective amount of fentanyl across the skin of a patient," the company reported in a press release. "The matrix device is configured by incorporating fentanyl into an adhesive matrix made of a copolymer containing alkyl acrylate and other monomers."
3M reports that it is open to licensing this technology to other interested parties.
STADA reportedly is one of the five leading companies in the generics industry and is represented in more than 30 countries with approximately 50 subsidiaries. Its branded products such as Mobilat, Grippostad and Ladival are among the highest selling in their product category in Germany.
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M's inhalation, transdermal or microneedle drug delivery technology. For more details, visit www.3M.com/dds.